Joseph P. Lyssikatos Sells 12,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph P. Lyssikatos sold 12,000 shares of the stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $22.49, for a total transaction of $269,880.00. Following the transaction, the insider now directly owns 1,077,936 shares in the company, valued at $24,242,780.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Enliven Therapeutics Stock Down 2.1 %

ELVN opened at $21.74 on Thursday. The stock’s 50 day moving average price is $23.14 and its two-hundred day moving average price is $20.72. The firm has a market capitalization of $1.02 billion, a P/E ratio of -11.26 and a beta of 1.09. Enliven Therapeutics, Inc. has a 12-month low of $9.80 and a 12-month high of $27.67.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.17. As a group, analysts anticipate that Enliven Therapeutics, Inc. will post -2.02 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Baird R W raised Enliven Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Robert W. Baird assumed coverage on shares of Enliven Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 price objective for the company.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ELVN. The Manufacturers Life Insurance Company acquired a new stake in Enliven Therapeutics during the second quarter worth about $322,000. Marshall Wace LLP bought a new stake in shares of Enliven Therapeutics in the 2nd quarter worth approximately $4,489,000. First Turn Management LLC acquired a new stake in shares of Enliven Therapeutics during the 2nd quarter worth approximately $9,657,000. Nicholas Investment Partners LP bought a new stake in shares of Enliven Therapeutics during the second quarter valued at approximately $1,310,000. Finally, American Century Companies Inc. raised its stake in shares of Enliven Therapeutics by 44.7% in the second quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock valued at $646,000 after purchasing an additional 8,540 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.